Streetbeat News

Price Targets

CPNG

Bernstein analyst Bokyung Suh has upgraded Coupang (NYSE:CPNG) from Underperform to Outperform, setting a new price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 9:48 am

HSY

Bernstein analyst Alexia Howard has downgraded Hershey (NYSE:HSY) from Outperform to Market Perform and reduced the price target from $230 to $205.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 9:39 am

CLMT

HC Wainwright & Co. analyst Amit Dayal has reiterated a Buy rating for Calumet (NASDAQ:CLMT) and maintained a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 9:35 am

RVMD

Needham analyst Ami Fadia has reiterated a Buy rating on Revolution Medicines (NASDAQ:RVMD) and maintained a price target of $61.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 9:30 am

CAG

COIN

HUM

MRNA

NKE

RIVN

STLA

Several large-cap stocks, including Humana, Stellantis, and Coinbase, experienced significant declines last week due to various factors such as performance updates, sales declines, and regulatory issues.

Portfolio Pulse from Lekha Gupta

October 06, 2024 | 5:13 pm

BEKE

BGNE

FANG

FUTU

JD

LI

PDD

VST

ZTO

US-listed Chinese stocks, including Futu Holdings, KE Holdings, JD.com, and others, saw significant gains last week due to China's economic stimulus measures. Other notable gainers included Vistra Corp and Diamondback Energy, driven by analyst upgrades.

Portfolio Pulse from Lekha Gupta

October 06, 2024 | 4:43 pm

IR

CFRA analyst Jonathan Sakraida maintains a Hold rating on Ingersoll Rand (NYSE:IR) and raises the price target from $85 to $95.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 9:55 pm

NEM

Over the past three months, 7 analysts have evaluated Newmont (NYSE:NEM), with a majority holding bullish views. The average 12-month price target has increased by 17.56% to $59.57. Analysts have raised their ratings and price targets, reflecting positive sentiment towards Newmont's market position and financial performance.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 9:02 pm

SRPT

In the past three months, 12 analysts have rated Sarepta Therapeutics (NASDAQ:SRPT), with most being somewhat bullish. The average 12-month price target is $177.83, a slight decline from previous estimates. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Sarepta's recent revenue growth and net margin are strong, but its ROE is below industry averages.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 8:01 pm

ZS

Zscaler (NASDAQ:ZS) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month average price target of $212.68, which is lower than the previous average of $228.48. Recent evaluations show several analysts lowering their price targets, reflecting a cautious outlook despite Zscaler's strong revenue growth. The company's financial metrics, such as net margin and ROE, are below industry averages, indicating potential profitability challenges.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 8:00 pm